PVCT News and Press, Provectus Biopharmaceuticals Inc From 06/22/20

PV-10 treatment leads to STING dimerization Researchers identify potential association of heat shock proteins with STING in PV-10-treated models KNOXVILLE, TN, June 22, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that data from ongoing preclinical stud...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

2020 India patent follows 2018 India patent that protects Provectus’ proprietary API manufacturing process Provectus further expands cancer combination therapy IP protection by filing new USPTO patent application for immunotherapy triplet combination of PV-10, CTLA-4, and PD-1 K...

Treatment refractory, immunologically cold, hepatic tumor type 37% reduction and 83% stabilization of treated disease (2D-EASL) Overall survival of 11 months for checkpoint inhibition-naïve patients; 11.4 months for checkpoint inhibition-refractory patients KNOXVILLE, TN, June 01...

Treatment refractory, immunologically cold, hepatic tumor type 50% reduction of treated disease; 83% stabilization of overall patient disease (RECIST) Median progression-free survival not reached (by CT scan; RECIST) Overall survival > 22.5 months; ongoing follow-up for 50% of patie...

KNOXVILLE, TN, May 18, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce the publication of an abstract about and data from ongoing preclinical study of investigational autolytic cancer immunotherapy PV-10 (rose bengal disodium) for the American Association for C...

KNOXVILLE, TN, April 29, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that abstracts about and data from our clinical trials of investigational autolytic cancer immunotherapy PV-10 (rose bengal disodium) as a single-agent for the treatment of neuroendocri...

KNOXVILLE, TN, April 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today said that data from its clinical trial of autolytic cancer immunotherapy PV-10 (rose bengal disodium) as a single-agent and in combination with immune checkpoint blockade for the treatment of primary or metastat...

KNOXVILLE, TN, March 17, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today said that data from ongoing research into investigational lysosomal-targeting cancer immunotherapy PV-10 (rose bengal disodium) for the treatment of solid tumor and blood cancers had been accepted for presentati...

13 patients treated to date have received single-agent PV-10 or combination of PV-10 and standard of care checkpoint blockade Independent safety profiles of PV-10 and checkpoint inhibition were maintained 32% ORR and 82% DCR of injected visceral hepatic target lesions (2D EASL) KNOXVI...